Announcing IndieBio’s 4th Class
IndieBio is excited to announce our newest class of thirteen biotech startups. These companies are bringing innovation to a host of industries, from classical biotech spaces like drug development and medical devices all the way to veterinary, information storage, and utilities markets.
While these companies will be based in downtown San Francisco for the next four months, all their technologies will have global impact.
A2A Pharmaceuticals designs computationally pre-optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections.
Animal Microbiome helps the monitoring and treatment of chronic health conditions in animals by providing a novel microbiome testing service.
BioInspira has developed a virus-based sensor network which will enable detection of airborne chemicals remotely and in real time, creating the next generation of infrastructure for industry.
Catalog is harnessing DNA to store the world’s information.
DxRx is a scalable digital health medical practice treating early stage alcohol addiction through telemedicine and behavior modification.
GEA Enzymes creates designer proteins by finding and manipulating specific enzyme activity. They make enzymes for the food industry that reduce saturated fat levels while maintaining consistent aroma, taste, and feel.
Mendel Health automates matching cancer patients to clinical trials through personal medical history and genetic analysis.
NeuroQore is commercializing an innovative new repetitive transcranial magnetic stimulation (rTMS) therapy system for treatment of depression and a range of other psychiatric and neurological disorders. rTMS is an emerging therapeutic brain stimulation technique that does not require anesthesia or have cognitive side effects.
Pure Cultures develops and manufactures novel prebiotics and probiotics to support the health of animals and reduce antibiotics in our food chain.
Ravata Solutions is transforming transgenic model development through automation with an aim of increasing pre-clinical medical discovery and innovation by 10–100x.
Scaled Biolabs is accelerating biologic, gene, and cell therapies using smart microfluidic chips. Thousands of cell experiments can be parallelized and automated on their lab-on-a-chip system, increasing throughput, precision, economy, and insight that can lead to dramatic innovations in organogenesis, fermentation condition optimization and therapeutic production.
Venomyx is bringing antivenom into the 21st century with the world’s first toxin-specific snake antivenom. Their solution will make antivenom treatment safe, effective, and affordable for the millions of snakebite victims per year around the world that are currently underserved.
ViaeX creates biological nanofiltration systems for water and air which are 400% more efficient than current solutions and enable selective pollutant and bacteria targeting. These systems are biodegradable, low cost, and rapidly scalable to enable fast deployment in cities around the world facing serious pollution issues.